The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...
Ribociclib—a drug already used to treat breast cancer—may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. A team of scientists from The Institute of Cancer ...
Some results have been hidden because they may be inaccessible to you